Abstract
QT prolongation is associated with increased risk of cardiac arrhythmias. Identifying the genetic variants that mediate antipsychotic induced prolongation may help to minimize this risk, which might prevent the removal of efficacious drugs from the market. We performed candidate gene analysis and five drug specific genome-wide association studies (GWAS) with 492K SNPs to search for genetic variation mediating antipsychotic induced QT prolongation in 738 schizophrenia patients from the Clinical Antipsychotic Trial of Intervention Effectiveness (CATIE) study.Our candidate gene study suggests the involvement of NOS1AP and NUBPL (p-values =1.45×10−05 and 2.66×10−13, respectively). Furthermore, our top GWAS hit achieving genome-wide significance, defined as a q-value <0.10, (p-value =1.54×10−7, q-value =0.07), located in SLC22A23, mediated the effects of quetiapine on prolongation. SLC22A23 belongs to a family of organic ion transporters that shuttle a variety of compounds including drugs, environmental toxins, and endogenous metabolites across the cell membrane. This gene is expressed in the heart and is integral in mouse heart development. The genes mediating antipsychotic induced QT prolongation partially overlap with the genes affecting normal QT interval variation. However, some genes may also be unique for drug induced prolongation. This study demonstrates the potential of GWAS to discover genes and pathways that mediate antipsychotic induced QT prolongation.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.